Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GTx, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'GTx, Inc. - Product Pipeline Review - 2014', provides an overview of the GTx, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of GTx, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of GTx, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of GTx, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the GTx, Inc.'s pipeline products Reasons to buy - Evaluate GTx, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of GTx, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the GTx, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of GTx, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of GTx, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of GTx, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 GTx, Inc. Snapshot 5 GTx, Inc. Overview 5 Key Information 5 Key Facts 5 GTx, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 GTx, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 GTx, Inc. - Pipeline Products Glance 11 GTx, Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 GTx, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 GTx, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 GTx, Inc. - Drug Profiles 15 enobosarm 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 GTx-758 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Gtx-027 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Beta-LGND2 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Gtx-186 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Gtx-230 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Inhibit AKR1C3 for Prostate Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Inhibit Tubulin for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 GTx, Inc. - Pipeline Analysis 25 GTx, Inc. - Pipeline Products by Target 25 GTx, Inc. - Pipeline Products by Route of Administration 27 GTx, Inc. - Pipeline Products by Molecule Type 28 GTx, Inc. - Pipeline Products by Mechanism of Action 29 GTx, Inc. - Recent Pipeline Updates 31 GTx, Inc. - Dormant Projects 40 GTx, Inc. - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 GTx-758 41 toremifene citrate 41 GTx, Inc. - Company Statement 42 GTx, Inc. - Locations And Subsidiaries 48 Head Office 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables GTx, Inc., Key Information 5 GTx, Inc., Key Facts 5 GTx, Inc. - Pipeline by Indication, 2014 8 GTx, Inc. - Pipeline by Stage of Development, 2014 9 GTx, Inc. - Monotherapy Products in Pipeline, 2014 10 GTx, Inc. - Phase III, 2014 11 GTx, Inc. - Phase II, 2014 12 GTx, Inc. - Phase I, 2014 13 GTx, Inc. - Preclinical, 2014 14 GTx, Inc. - Pipeline by Target, 2014 26 GTx, Inc. - Pipeline by Route of Administration, 2014 27 GTx, Inc. - Pipeline by Molecule Type, 2014 28 GTx, Inc. - Pipeline Products by Mechanism of Action, 2014 30 GTx, Inc. - Recent Pipeline Updates, 2014 31 GTx, Inc. - Dormant Developmental Projects,2014 40 GTx, Inc. - Discontinued Pipeline Products, 2014 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.